Professor Chris Probert MD FRCP FHEA
Professor of Gastroenterology Molecular & Clinical Cancer Medicine
- +44 (0)151 795 4010 /
- Work email Chris.Probert@liverpool.ac.uk
Research
Metabolomics
Recently, most of my research has be directed towards volatile organic compounds and their use as biomarkers of IBS, IBD and various cancers.
The intestinal microbiome and mycobiome
My group also looks at the microbiome and mycobiome of the intestine in humans, mice and equines.
Clinical interests
I have an ongoing-interest in IBD and IBS.
Research Grants
Mechanisms Affecting the Gut of Preterm Infants in Enteral feeding trials (MAGPIE)
DEPARTMENT OF HEALTH & SOCIAL CARE (UK)
February 2016 - September 2019
VOID-bladder cancer
CANCER RESEARCH UK (UK)
January 2017 - April 2019
IASO: A phase II randomised placebo controlled double blind trial of Interleukin 1 blockade in Acute Severe Colitis
DEPARTMENT OF HEALTH & SOCIAL CARE (UK)
March 2017 - October 2022
Characterization of the gut mycobiome in an inception cohort of paediatric inflammatory bowel disease patients
GUTS (UK CHARITY)
April 2018 - March 2019
Understanding the mechanisms for the variation in beneficial effects of dietary fibre in IBS: an old concept in new light
DEPARTMENT FOR BUSINESS, ENERGY AND INDUSTRIAL STRATEGY (BEIS) (UK)
August 2016 - January 2021
MECNUT: Impact of dietary exposure to emulsifiers on the intestinal mucosa - implications for inflammatory bowel disease and metabolic syndrome
MEDICAL RESEARCH COUNCIL
November 2017 - September 2021
Volatile Organic compounds for the DEtection of Colorectal cAncer: VODECA
CANCER RESEARCH UK (UK)
November 2018 - July 2023
Investigation of octen-3-ol, a fungal metabolite, in faeces of people with Parkinson’s disease
WELLCOME TRUST (UK)
July 2015 - August 2015
Study to determine the effect of ferric maltol on gut microbiota in inflammatory bowel disease patients with iron deficiency
SHIELD THERAPEUTICS PLC (UK)
January 2018 - January 2019
Peripheral blood gene expression profiling as predictors of response to biological therapy in ulcerative colitis
CROHN'S AND COLITIS UK (UK)
September 2016 - October 2021
Diarrhoea Diagnostic Device: From Bench to Bedside
WELLCOME TRUST (UK)
October 2014 - December 2015
Impact Acceleration Account - University of Liverpool 2012
ENGINEERING & PHYSICAL SCIENCES RESEARCH COUNCIL
October 2012 - March 2017
Examination of the fungal microbiome in Crohn’s disease and an investigation of the impact of fungi on bacterial microbiota and their interaction with phagocytic leucocytes
NAT ASSOC FOR COLITIS & CROHNS DISEASE (UK)
September 2015 - August 2017
Evaluation of faecal volatile organic compounds in the diagnosis of paediatric inflammatory bowel disease
DEPARTMENT OF HEALTH & SOCIAL CARE (UK)
April 2017 - September 2020
The role of faecal and urinary Volatile Organic Compounds (VOCs) as a non-invasive diagnostic biomarker of colorectal cancer
SHIRE PHARMACEUTICALS LIMITED (UK)
May 2015 - April 2017
The role of urinary volatile organic compounds as a biomarker for hepatocellular carcinoma
ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)
August 2015 - July 2016
Can Volatile Organic Compounds be used to detect Campylobacter infection in Poultry Houses?
ROBOSCIENTIFIC LIMITED (UK)
October 2012 - March 2013
Systems medicine of chronic inflammatory bowel disease (SysmedIBD)
EUROPEAN COMMISSION
December 2012 - November 2017
Faecal Microbiota in Preterm Infants Developing Necrotising Enterocolitis (NEC) - The DOVEtail Study.
ACTION MEDICAL RESEARCH (UK), BIRMINGHAM CHILDREN'S HOSPITAL (UK)
September 2012 - October 2015
The role of faecal Volatile Organic Compounds (VOCs) as a non-invasive diagnostic biomarker of colorectal cancer (pilot study)
ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)
January 2014 - June 2015
Influence of iron supplementation on gut flora and the natural history of Inflammatory Bowel Disease
LIBYAN EMBASSY IN LONDON🚩
April 2013 - March 2015
Analysis of volatile organic compounds (VOCs) emitted from the faeces of preterm infants as a predictor of preclinical necrotising enterocolitis (NEC).
ACTION MEDICAL RESEARCH (UK)
October 2012 - February 2016
Trial of antibiotics and hydroxychloroquine in Crohn's disease
NAT ASSOC FOR COLITIS & CROHNS DISEASE (UK)
October 2013 - March 2020